About summit therapeutics inc - SMMT
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.
SMMT At a Glance
Summit Therapeutics, Inc.
601 Brickell Key Drive
Miami, Florida 33131
| Phone | 1-305-203-2034 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -221,315,000.00 | |
| Sector | Health Technology | Employees | 159 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
SMMT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 33.86 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -58.788 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.001 |
SMMT Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,391,918.239 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
SMMT Liquidity
| Current Ratio | 10.155 |
| Quick Ratio | 10.155 |
| Cash Ratio | 9.889 |
SMMT Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -69.322 |
| Return on Equity | -94.895 |
| Return on Total Capital | -55.892 |
| Return on Invested Capital | -77.223 |
SMMT Capital Structure
| Total Debt to Total Equity | 1.857 |
| Total Debt to Total Capital | 1.823 |
| Total Debt to Total Assets | 1.657 |
| Long-Term Debt to Equity | 0.888 |
| Long-Term Debt to Total Capital | 0.872 |